Shanghai Fosun Pharma Group Co., Ltd. ("Fosun Pharma") announced on October 30, 2024, that it provided guarantees for its holding subsidiary. Fosun Pharma provided joint liability guarantee for the RMB 50 million revolving capital loan applied by its holding subsidiary Fosun Health to Shanghai Rural Commercial Bank, and provided the same guarantee for the special acquisition loan not exceeding RMB 160 million applied by Fosun Pharma Industry to China Everbright Bank. The guarantee was within the scope authorized by the 2023 shareholders' meeting and within the quota range approved by the shareholders' meeting. As of the announcement date, Fosun Pharma Group's actual external guarantee amount amounted to approximately RMB 30,734.04 million, accounting for approximately 67.27% of the audited attributable net assets of the listed company at the end of 2023. The announcement pointed out that the risk of this guarantee is relatively controllable, necessary, and reasonable.

Shanghai Fosun Pharma Group Co., Ltd. ("Fosun Pharma") announced on October 30, 2024, that it provided guarantees for its holding subsidiary. Fosun Pharma provided joint liability guarantee for the RMB 50 million revolving capital loan applied by its holding subsidiary Fosun Health to Shanghai Rural Commercial Bank, and provided the same guarantee for the special acquisition loan not exceeding RMB 160 million applied by Fosun Pharma Industry to China Everbright Bank. The guarantee was within the scope authorized by the 2023 shareholders' meeting and within the quota range approved by the shareholders' meeting. As of the announcement date, Fosun Pharma Group's actual external guarantee amount amounted to approximately RMB 30,734.04 million, accounting for approximately 67.27% of the audited attributable net assets of the listed company at the end of 2023. The announcement pointed out that the risk of this guarantee is relatively controllable, necessary, and reasonable.